RESAPP HEALTH LIMITED – VOLUNTARY SUSPENSION EXTENSION
Further to the request on 2 June 2022 for the securities of ResApp Health Limited (“Company” to be placed in voluntary suspension, the Company hereby requests that the voluntary suspension be extended pending the release of an announcement by the Company providing an update as to the status of the proposed acquisition by Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) of 100% of shares in the Company by way of a Scheme of Arrangement.
The Company requests that the voluntary suspension ends on the date the anticipated announcement referred to above is released to the market which the Company anticipates will occur by Wednesday 8 June 2022. The Company is not aware of any reason why the voluntary suspension should not be granted, or of any other information necessary to inform the market about the suspension. This request has been authorised for release to ASX by the Company's Board of Directors.
RAP Price at posting:
11.0¢ Sentiment: Buy Disclosure: Held
to be placed in voluntary suspension, the Company hereby requests that the voluntary suspension be extended pending the release of an announcement by the Company providing an update as to the status of the proposed acquisition by Pfizer Australia Holdings Pty Limited (a wholly-owned subsidiary of Pfizer Inc, a global biopharmaceutical company) of 100% of shares in the Company by way of a Scheme of Arrangement.
